🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. bempedoic acid

    Esperion Therapeutics

    Hypercholesterolemia

    phase 3 small molecule completed

    5 trials

  2. bempegaldesleukin

    Nektar Therapeutics UK Limited

    Renal Cell Carcinoma

    phase 3 mab terminated

    1 trial

  3. bevacizumab

    Outlook Therapeutics NL B. V.

    Neovascular Age-related Macular Degeneration

    phase 3 mab completed

    1 trial

  4. bevacizumab

    Outlook Therapeutics NL B. V.

    Age-related Macular Degeneration

    phase 3 mab active

    4 trials

  5. blisibimod

    Santhera Pharmaceuticals (Deutschland) GmbH

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    1 trial

  6. bupivacaine liposome injectable suspension

    Pacira Ireland Limited

    Pain, Postoperative

    phase 3 small molecule active

    1 trial

  7. casirivimab+imdevimab combination therapy

    Regeneron UK Limited

    COVID-19

    phase 3 small molecule terminated

    1 trial

  8. centrally blinded product containing all the same manufactured ingredients and excipients as the DM199 formulation, except for the active pharmaceutical ingredient (API).

    DiaMedica Therapeutics

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  9. chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Limited Stage Small Cell Lung Cancer

    phase 3 other active

    1 trial

  10. cisplatin

    United Therapeutics Europe Ltd

    Bladder Cancer

    phase 3 small molecule completed

    1 trial

  11. cyclophosphamide

    Partner Therapeutics Limited

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  12. delandistrogene moxeparvovec

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 gene therapy active

    7 trials

  13. deucravacitinib, Placebo to match BMS 986165 tablet

    Bristol-Myers Squibb Australia Pty Ltd

    Moderate-to-Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  14. deucravacitinib, Placebo to match deucravacitinib 6mg tablets in bottle, oral use, deucravacitinib, Placebo to match deucravacitinib 2mg minitablets in sachet, oral use

    Bristol-Myers Squibb Australia Pty Ltd

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  15. different degrees of adjustment of the injection interval

    The First People's Hospital of Lianyungang

    Exudative Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  16. doxorubicin hydrochloride

    United Therapeutics Europe Ltd

    Stage III Bladder Cancer

    phase 3 small molecule completed

    1 trial

  17. doxorubicin in combination with palifosfamide-tris

    Alaunos Therapeutics

    Soft Tissue Sarcoma

    phase 3 small molecule completed

    1 trial

  18. dupilumab

    Regeneron UK Limited

    Moderate to Severe Atopic Hand and Foot Dermatitis

    phase 3 small molecule completed

    1 trial

  19. eRapa (encapsulated rapamycin)

    Biodexa Pharmaceuticals Plc

    Familial Adenomatous Polyposis (FAP)

    phase 3 small molecule active

    1 trial

  20. educational internet site on prostate cancer screening

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 3 other completed

    1 trial

  21. eteplirsen

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 3 small molecule completed

    2 trials

  22. evorpacept, Herceptin 150 mg powder for concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/mL concentrate for solution for infusion, Normal Saline (Sodium Chloride)

    Wuhan Createrna Science and Technology Co., Ltd

    Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)

    phase 3 small molecule active

    1 trial

  23. exemestane

    Partner Therapeutics Limited

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  24. extended-release guanfacine hydrochloride (SPD503)

    Takeda

    Attention-Deficit/Hyperactivity Disorder

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources